Element | Case-patient 1 | Case-patient 2 | Case-patient 3 | Case-patient 4 |
---|---|---|---|---|
Patient history | ||||
Known exposure in RMSF-epidemic area of Mexico | + | + | + | |
Evidence of receipt of medical care in Mexico | + | + | ||
Prescribed nontetracycline antimicrobial drug | + | + | + | + |
Signs and symptoms at initial presentation | ||||
Fever | + | + | + | + |
Headache | + | + | ||
Nausea/vomiting/diarrhea | + | + | ||
Rash | ||||
Severe end-stage manifestations | ||||
Skin necrosis | + | + | + | |
Rash | + | + | + | + |
Respiratory failure | + | + | + | + |
Disseminated intravascular coagulation | + |
*RMSF, Rocky Mountain spotted fever; +, present; blank cells, absent.
This activity is intended for infectious disease practitioners, internists, intensivists, pulmonologists, public health officials, and other clinicians caring for patients with presumed or diagnosed Rocky Mountain spotted fever.
The goal of this activity is to describe clinical features and recommended management of Rocky Mountain spotted fever in patients with rapidly progressing febrile illness and recent exposure in northern Mexico, based on a series of 4 fatal cases.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
processing....
During 2013–2016, the Arizona Department of Health Services, the California Department of Public Health (CDPH), and the US Centers for Disease Control and Prevention (CDC) identified 4 cases of RMSF in persons who acquired the illness in Mexico and later died in the United States ( Table 1 ). The cases were identified during the course of routine surveillance and diagnostic testing for this disease at the respective state public health laboratories or CDC. To better characterize the epidemiologic risk factors, clinical progression, and treatment course associated with each of these deaths, we performed a retrospective review of clinical and epidemiologic data and, when available, medical charts. Because the CDC Human Subjects Review Committee determined that this evaluation was not research, this case series was exempt from institutional review board and human subjects review.